Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Observations of Reduced Turbulence and Wave Activity in the Arctic Middle Atmosphere Following the January 2015 Sudden Stratospheric Warming.

Triplett CC, Li J, Collins RL, Lehmacher GA, Barjatya A, Fritts DC, Strelnikov B, Lübken FJ, Thurairajah B, Harvey VL, Hampton DL, Varney RH.

J Geophys Res Atmos. 2018 Dec 16;123(23):13259-13276. doi: 10.1029/2018JD028788. Epub 2018 Nov 12.

2.

Rationale and design of the HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) Trial: a protocol for an international randomised controlled trial evaluating early surgery for hip fracture patients.

Borges FK, Bhandari M, Patel A, Avram V, Guerra-Farfán E, Sigamani A, Umer M, Tiboni M, Adili A, Neary J, Tandon V, Sancheti PK, Lawendy A, Jenkinson R, Ramokgopa M, Biccard BM, Szczeklik W, Wang CY, Landoni G, Forget P, Popova E, Wood G, Nabi Nur A, John B, Ślęczka P, Feibel RJ, Balaguer-Castro M, Deheshi B, Winemaker M, de Beer J, Kolesar R, Teixidor-Serra J, Tomas-Hernandez J, McGillion M, Shanthanna H, Moppett I, Vincent J, Pettit S, Harvey V, Gauthier L, Alvarado K, Devereaux PJ.

BMJ Open. 2019 May 1;9(4):e028537. doi: 10.1136/bmjopen-2018-028537.

3.

Lidar Observations of Stratospheric Gravity Waves From 2011 to 2015 at McMurdo (77.84°S, 166.69°E), Antarctica: 2. Potential Energy Densities, Lognormal Distributions, and Seasonal Variations.

Chu X, Zhao J, Lu X, Harvey VL, Jones RM, Becker E, Chen C, Fong W, Yu Z, Roberts BR, Dörnbrack A.

J Geophys Res Atmos. 2018 Aug 16;123(15):7910-7934. doi: 10.1029/2017JD027386. Epub 2018 Aug 6.

4.

Characteristics of Emergency Department Visits and Select Predictors of Hospitalization for Adults With Newly Diagnosed Cancer in a Safety-Net Health System.

Hong AS, Sadeghi N, Harvey V, Lee SC, Halm EA.

J Oncol Pract. 2019 Jun;15(6):e490-e500. doi: 10.1200/JOP.18.00614. Epub 2019 Apr 9.

PMID:
30964735
5.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A.

Breast Cancer Res. 2019 Mar 11;21(1):39. doi: 10.1186/s13058-019-1115-2.

6.

Bias in survival estimates created by a requirement for consent to enter a clinical breast cancer registry.

Elwood JM, Marshall RJ, Tin ST, Barrios MEP, Harvey VJ.

Cancer Epidemiol. 2019 Feb;58:178-183. doi: 10.1016/j.canep.2018.12.005.

PMID:
30639876
7.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.

J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.

PMID:
30475668
8.

Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.

Elwood JM, Tawfiq E, TinTin S, Marshall RJ, Phung TM, Campbell I, Harvey V, Lawrenson R.

BMC Cancer. 2018 Sep 17;18(1):897. doi: 10.1186/s12885-018-4791-x.

9.

Postoperative Remote Automated Monitoring: Need for and State of the Science.

McGillion MH, Duceppe E, Allan K, Marcucci M, Yang S, Johnson AP, Ross-Howe S, Peter E, Scott T, Ouellette C, Henry S, Le Manach Y, Paré G, Downey B, Carroll SL, Mills J, Turner A, Clyne W, Dvirnik N, Mierdel S, Poole L, Nelson M, Harvey V, Good A, Pettit S, Sanchez K, Harsha P, Mohajer D, Ponnambalam S, Bhavnani S, Lamy A, Whitlock R, Devereaux PJ; PROTECT Network Investigators.

Can J Cardiol. 2018 Jul;34(7):850-862. doi: 10.1016/j.cjca.2018.04.021. Epub 2018 Apr 25. Review.

10.

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H.

JAMA Oncol. 2018 Sep 1;4(9):1199-1206. doi: 10.1001/jamaoncol.2018.1380.

11.

Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.

Corter AL, Broom R, Porter D, Harvey V, Findlay M.

Psychooncology. 2018 Sep;27(9):2096-2103. doi: 10.1002/pon.4771. Epub 2018 Jun 14.

PMID:
29776011
12.

The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer.

Lawrenson R, Lao C, Campbell I, Harvey V, Seneviratne S, Elwood M, Sarfati D, Kuper-Hommel M.

N Z Med J. 2018 May 18;131(1475):51-60.

PMID:
29771902
13.
14.

Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?

Tin Tin S, Elwood JM, Brown C, Sarfati D, Campbell I, Scott N, Ramsaroop R, Seneviratne S, Harvey V, Lawrenson R.

BMC Cancer. 2018 Jan 8;18(1):58. doi: 10.1186/s12885-017-3797-0.

15.

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortés J.

Eur J Cancer. 2018 Jan;89:27-35. doi: 10.1016/j.ejca.2017.10.021. Epub 2017 Dec 8.

PMID:
29223479
16.

Laugier-Hunziker syndrome.

Paul J, Harvey VM, Sbicca JA, O'Neal B.

Cutis. 2017 Sep;100(3):E17-E19. No abstract available.

PMID:
29121134
17.

Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes.

Lawrenson R, Lao C, Campbell I, Harvey V, Seneviratne S, Edwards M, Elwood M, Scott N, Kidd J, Sarfati D, Kuper-Hommel M.

Cancer Causes Control. 2017 Dec;28(12):1417-1427. doi: 10.1007/s10552-017-0969-9. Epub 2017 Oct 13.

PMID:
29027594
18.

Prostaglandin D2 Uses Components of ROS Signaling to Enhance Testosterone Production in Keratinocytes.

Mantel A, McDonald JT, Goldsborough K, Harvey VM, Chan J.

J Investig Dermatol Symp Proc. 2017 Oct;18(2):S81-S84. doi: 10.1016/j.jisp.2017.01.003.

19.

From Bench to Bedside: The Hampton University Skin of Color Research Institute 2015 Skin of Color Symposium.

Enos CW, Harvey VM.

J Investig Dermatol Symp Proc. 2017 Oct;18(2):S29-S30. doi: 10.1016/j.jisp.2016.10.001.

20.

The use of trastuzumab in New Zealand women with breast cancer.

Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e152-e160. doi: 10.1111/ajco.12766. Epub 2017 Aug 30.

PMID:
28856817
21.

The Role of Neighborhood Characteristics in Late Stage Melanoma Diagnosis among Hispanic Men in California, Texas, and Florida, 1996-2012.

Harvey VM, Enos CW, Chen JT, Galadima H, Eschbach K.

J Cancer Epidemiol. 2017;2017:8418904. doi: 10.1155/2017/8418904. Epub 2017 Jun 18.

22.

Melanoma Disparities among US Hispanics: Use of the Social Ecological Model to Contextualize Reasons for Inequitable Outcomes and Frame a Research Agenda.

Harvey VM, Oldfield CW, Chen JT, Eschbach K.

J Skin Cancer. 2016;2016:4635740. doi: 10.1155/2016/4635740. Epub 2016 Aug 29. Review.

23.

Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?

Tin Tin S, Elwood JM, Lawrenson R, Campbell I, Harvey V, Seneviratne S.

PLoS One. 2016 Apr 7;11(4):e0153206. doi: 10.1371/journal.pone.0153206. eCollection 2016.

24.

Fluoroscopy-induced chronic radiation dermatitis (FICRD) after endovascular abdominal aortic aneurysm endoleak repair.

Lyons AB, Harvey VM, Gusev J.

JAAD Case Rep. 2015 Nov 23;1(6):403-5. doi: 10.1016/j.jdcr.2015.09.022. eCollection 2015 Nov. No abstract available.

25.

A rare case of late-onset lichenoid photodermatitis after vandetanib therapy.

Bota J, Harvey V, Ferguson C, Hood A.

JAAD Case Rep. 2015 May 25;1(3):141-3. doi: 10.1016/j.jdcr.2015.03.008. eCollection 2015 May. No abstract available.

26.

Oral melanoma in a gravid, HIV-positive woman.

Lyons AB, Warren MP, Ferguson C, Katdare M, Harvey VM.

JAAD Case Rep. 2015 May 2;1(3):120-2. doi: 10.1016/j.jdcr.2015.02.011. eCollection 2015 May. No abstract available.

27.

Collagen Fingerprinting: A New Screening Technique for Radiocarbon Dating Ancient Bone.

Harvey VL, Egerton VM, Chamberlain AT, Manning PL, Buckley M.

PLoS One. 2016 Mar 3;11(3):e0150650. doi: 10.1371/journal.pone.0150650. eCollection 2016.

28.

Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology.

Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I.

BMC Cancer. 2016 Feb 19;16:129. doi: 10.1186/s12885-016-2177-5.

29.

Keloids and Hypertrophic Scars: A Spectrum of Clinical Challenges.

Trace AP, Enos CW, Mantel A, Harvey VM.

Am J Clin Dermatol. 2016 Jun;17(3):201-23. doi: 10.1007/s40257-016-0175-7. Review.

PMID:
26894654
30.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.

PMID:
26874901
31.

Patient-provider communication, concordance, and ratings of care in dermatology: Results of a cross-sectional study.

Harvey VM, Ozoemena U, Paul J, Beydoun HA, Clemetson NN, Okoye GA.

Dermatol Online J. 2016 Nov 15;22(11). pii: 13030/qt06j6p7gh.

PMID:
28329560
32.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM; BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55. doi: 10.1007/s10549-015-3634-6. Epub 2015 Nov 21.

33.

IMAGES IN CLINICAL MEDICINE. Acral Lentiginous Melanoma.

Warren MP, Harvey VM.

N Engl J Med. 2015 Nov 5;373(19):1864. doi: 10.1056/NEJMicm1500906. No abstract available.

34.

Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.

North RT, Harvey VJ, Cox LC, Ryan SN.

Clinicoecon Outcomes Res. 2015 Jul 29;7:423-30. doi: 10.2147/CEOR.S85599. eCollection 2015.

35.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

36.

P2X7/PANX1 as a new target for melanoma?

Mantel A, Harvey V.

Exp Dermatol. 2015 May;24(5):336-7. doi: 10.1111/exd.12633. Epub 2015 Mar 9. No abstract available.

PMID:
25594260
37.

A pilot randomized controlled trial of a post-discharge program to support emerging adults with type 1 diabetes mellitus transition from pediatric to adult care.

Steinbeck KS, Shrewsbury VA, Harvey V, Mikler K, Donaghue KC, Craig ME, Woodhead HJ.

Pediatr Diabetes. 2015 Dec;16(8):634-9. doi: 10.1111/pedi.12229. Epub 2014 Nov 11.

PMID:
25385685
38.

Social determinants of racial and ethnic disparities in cutaneous melanoma outcomes.

Harvey VM, Patel H, Sandhu S, Wallington SF, Hinds G.

Cancer Control. 2014 Oct;21(4):343-9.

39.

Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C.

Beck K, Paul J, Sawardekar S, Harvey V.

J Dermatol Case Rep. 2014 Jun 30;8(2):46-9. doi: 10.3315/jdcr.2014.1171. eCollection 2014 Jun 30.

40.

Repetitive sequence variations in the promoter region of the adhesin-encoding gene sabA of Helicobacter pylori affect transcription.

Harvey VC, Acio CR, Bredehoft AK, Zhu L, Hallinger DR, Quinlivan-Repasi V, Harvey SE, Forsyth MH.

J Bacteriol. 2014 Oct;196(19):3421-9. doi: 10.1128/JB.01956-14. Epub 2014 Jul 14.

41.

Analysis of internet usage among cancer patients in a county hospital setting: a quality improvement initiative.

Wallace L, Lilley L, Lodrigues W, Dreadin-Pulliam J, Xie XJ, Mathur S, Rao M, Harvey V, Leitch AM, Rao R.

JMIR Res Protoc. 2014 May 9;3(2):e26. doi: 10.2196/resprot.2806.

42.

Does the use of tranexamic acid improve trauma mortality?

Harvey V, Perrone J, Kim P.

Ann Emerg Med. 2014 Apr;63(4):460-2. doi: 10.1016/j.annemergmed.2013.08.028. Epub 2013 Oct 3. Review. No abstract available.

PMID:
24095056
43.

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.

Lee CK, Gebski VJ, Coates AS, Veillard AS, Harvey V, Tattersall MH, Byrne MJ, Brigham B, Forbes J, Simes RJ; Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).

Springerplus. 2013 Aug 21;2:391. doi: 10.1186/2193-1801-2-391. eCollection 2013.

44.

Reply to: letter to the editor "subcutaneous herceptin therapy".

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Dec;53(12):1343-4. doi: 10.1002/jcph.172. Epub 2013 Sep 21. No abstract available.

PMID:
23996383
45.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R.

Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.

PMID:
23932548
46.

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J.

Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22.

PMID:
23704196
47.

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer.

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Jan 24. doi: 10.1177/0091270011436560. [Epub ahead of print]

PMID:
23504807
48.

A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.

Harvey VJ, Sharples KJ, Isaacs RJ, Jameson MB, Jeffery GM, McLaren BR, Pollard S, Riley GA, Simpson AB, Hinder VA, Scott JN, Dzhelali MV, Findlay MP.

Ann Oncol. 2013 Jul;24(7):1828-34. doi: 10.1093/annonc/mdt065. Epub 2013 Mar 4.

PMID:
23463624
49.

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Feb;53(2):192-201. doi: 10.1177/0091270012436560.

PMID:
23436264
50.

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A.

Ann Oncol. 2013 May;24(5):1203-11. doi: 10.1093/annonc/mds627. Epub 2013 Jan 4.

PMID:
23293111

Supplemental Content

Loading ...
Support Center